Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment

Next Previous
X
Search
Trial Profile

Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 May 2023 Planned End Date changed from 5 May 2022 to 5 Sep 2023.
    • 03 Feb 2023 Results assessing safety and efficacy of Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma published in the Journal of Clinical Oncology
    • 13 Sep 2022 Status has been changed to completed, as per Results presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top